BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Historical Holders from Q1 2016 to Q3 2025

Symbol
ONC on Nasdaq
Type / Class
Equity / Ordinary shares, par value $0.0001 per share
Shares outstanding
1.39B
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
32.9M
Holdings value
$11.2B
% of all portfolios
0.003%
Grand Portfolio weight change
-0.001%
Number of holders
257
Number of buys
148
Number of sells
-116
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HHLR ADVISORS, LTD. 4.9% -25.7% $16.8B -$5.94B 68.6M -26.1% HHLR Advisors, Ltd. 09 May 2025

Institutional Holders of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 32.9M $11.2B -$347M $340.70 257
2025 Q2 34.4M $8.34B -$2.1B $242.07 240
2025 Q1 42.5M $11.6B -$301M $272.17 260
2024 Q4 43.7M $8.07B -$576M $184.71 222
2024 Q3 46.5M $10.4B -$117M $224.51 221
2024 Q2 46.8M $6.68B +$49.5M $142.67 195
2024 Q1 46.4M $7.26B +$228M $156.39 198
2023 Q4 45M $8.11B -$359M $180.36 201
2023 Q3 46.9M $8.44B -$8.58M $179.87 195
2023 Q2 47M $8.39B -$134M $178.30 200
2023 Q1 47.7M $10.3B -$366M $215.53 214
2022 Q4 49.4M $10.9B -$822M $219.94 206
2022 Q3 53.5M $7.21B -$18.7M $134.82 204
2022 Q2 53.5M $8.67B -$222M $161.85 217
2022 Q1 54.9M $10.4B -$144M $188.60 228
2021 Q4 55.5M $15B -$243M $270.93 247
2021 Q3 56.1M $20.4B +$188M $363.00 242
2021 Q2 55.5M $19B -$144M $343.19 259
2021 Q1 55.9M $19.5B +$655M $348.08 241
2020 Q4 54.3M $14B -$184M $258.39 234
2020 Q3 54.8M $15.7B +$1.34B $286.44 238
2020 Q2 50.1M $9.44B +$214M $188.40 209
2020 Q1 49M $6.03B -$8.36M $123.11 205
2019 Q4 48.9M $8.11B -$139M $165.76 217
2019 Q3 50M $6.12B +$324M $122.46 192
2019 Q2 49.1M $6.09B +$19.1M $123.95 196
2019 Q1 47M $6.2B +$70.6M $132.00 193
2018 Q4 47.5M $6.65B -$438M $140.26 188
2018 Q3 45.5M $7.84B +$599M $172.22 142
2018 Q2 42.2M $6.49B +$893M $153.73 128
2018 Q1 36.4M $6.12B +$1.5B $168.00 122
2017 Q4 27.6M $2.69B +$229M $97.72 93
2017 Q3 25.2M $2.61B +$502M $103.46 81
2017 Q2 20.4M $918M +$131M $45.00 57
2017 Q1 17.6M $645M +$43.5M $36.61 54
2016 Q4 16.6M $504M +$195M $30.36 54
2016 Q3 10.2M $313M +$58.3M $30.81 38
2016 Q2 8.28M $241M +$16.6M $29.80 39
2016 Q1 7.72M $221M +$221M $29.31 40